Jaguar Animal Health, Inc. (JAGX)
Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its product pipeline consists of Mytesi(R), Canalevia(TM), Equilevia(TM) and Neonorm (TM). Jaguar Health Inc., formerly known as Jaguar Animal Health Inc., is based in San Francisco, United States.
Jaguar Animal Health, Inc. (JAGX)’s Financial Overview
Jaguar Animal Health, Inc. (JAGX) declined -7% yesterday to close its trading session at $0.19. The company has 1 year Price Target of $1.25. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 5.21 Million shares yesterday. The firm shows the market capitalization of $18.06 Million.
The firm is trading with SMA20 of -5.78 Percent, SMA50 of SMA50 Percent and SMA200 of -38.03 percent. Jaguar Animal Health, Inc. has P/S value of 6.45 while its P/B value stands at 0.33. Similarly, the company has Return on Assets of -30.2 percent, Return on Equity of -128.7 percent and Return on Investment of -978.1 Percent.
The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 1 analysts offering 12-month price forecasts for Jaguar Health Inc have a median target of 1.25, with a high estimate of 1.25 and a low estimate of 1.25. The median estimate represents a +572.04% increase from the last price of 0.19.
AstraZeneca PLC (AZN)
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
AstraZeneca PLC (AZN)‘s Financial Outlook
The 32 analysts offering 12-month price forecasts for AstraZeneca PLC have a median target of 38.04, with a high estimate of 50.17 and a low estimate of 24.92. The median estimate represents a +8.28% increase from the last price of 35.13.
According to Zacks Investment Research, AstraZeneca PLC has a Consensus Recommendation of 1.44. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged1.33% and closed its last trading session at $35.13. The company has the market capitalization of $88.98 Billion. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 5.12 Million shares. The company has a total of 2.53 Billion shares outstanding.
The company has YTD performance of 1.24 percent. Beta for AstraZeneca PLC stands at 0.64 while its ATR (average true range) is 0.5. The company has Weekly Volatility of 1.42%% and Monthly Volatility of 1.30%.
AstraZeneca PLC has distance from 20-day Simple Moving Average (SMA20) of 3.29%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of 5.26%.
The Company currently has ROA (Return on Assets) of 4.7 percent, Return on Equity (ROE) of 21.7 Percent and Return on Investment (ROI) of 13.1% with Gross margin of 81.6 percent and Operating & Profit margin of 16.4% and 13.4% respectively.